Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

Sponsor
Samsung Medical Center
Study ID
NCT01054781
Phase
PHASE2
Status
Completed

Conditions

  • Diffuse Large B-cell Lymphoma (DLBCL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    1st cycle R+R-CHOP 2-8th cycle R-CHOP

Study Details

The purpose of this study is to evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL

Key Dates

Start date
Jan 31, 2009
Status verified
Sep 2012
Primary completion
Nov 30, 2010

Study Design

Enrollment
91 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To evaluate the complete response (CR) rate after Intensified 1st cycle Rituximab plus 3rd cycles of R-CHOP in DLBCL and [ Time Frame: 12 months ]

Related Studies